Abu Dhabi, Eczema, often dismissed as “just a skin problem,” affects far more than the skin. For thousands of children in the UAE - and the families who care for them - it’s a relentless battle of itching, poor sleep, emotional distress, and social isolation. Parents stay up through the night tending to their children’s wounds, while children miss school, avoid friendships, and battle anxiety at a young age. This invisible epidemic is robbing too many families of comfort, confidence, and peace of mind.
In response to this growing healthcare challenge, Jamjoom Pharma and the Emirates Dermatology Society (EDS) have signed today a Memorandum of Understanding (MoU) to launch “ECZPLORE” —a pioneering awareness campaign aimed at changing the way eczema is understood, managed, and supported in the UAE.
“Eczema is not just a rash—it’s a chronic disease that affects the entire family,” said Dr. Ayman Al Naeem, President of the Emirates Dermatology Society. “We believe that early education and empathetic support can change the daily reality for children living with eczema. Recent studies suggest that 1 in 5 children in the UAE suffer from eczema, with over half of moderate-to-severe cases remaining uncontrolled. The condition not only disrupts sleep and school life, but also doubles the likelihood of anxiety and depression in caregivers, highlighting the urgent need for broader public awareness.”
The ECZPLORE program will roll out nationwide through schools, clinics, and digital channels. It includes child-friendly materials like coloring books and storybooks, adult-focused guides and magazines, and tailored support for healthcare professionals—all designed to help families better understand the condition and how to lead an “eczema-friendly” life.
“At Jamjoom Pharma, our purpose is to serve patient well-being through knowledge, care, and community support,” said Dr. Samer Lezzaiq, General Manager - Gulf, Levant & Export Markets at Jamjoom Pharma. “Through ECZPLORE, we aim to break the silence around eczema, equip caregivers with real tools, and give children the confidence to live without shame.”
The partnership also extends into fungal infection awareness, targeting both patients and professionals with actionable educational campaigns.
Together, Jamjoom Pharma and EDS hope to drive a cultural shift in how chronic skin conditions are perceived and managed, transforming frustration into understanding—and silence into support.
- End –
About Jamjoom Pharmaceuticals:
Jamjoom Pharma is a leading pharmaceutical organization committed to enhancing the quality of life through the development, manufacturing, and distribution of high-quality medicines and consumer healthcare products. Headquartered in Saudi Arabia, the company was established back in 2000 and is tirelessly operating to support the Saudi Vision 2030 to reinforce the public healthcare system.
With a strong focus on research, innovation, and patient-centered care, Jamjoom Pharma serves diverse markets across Middle East & Africa, with a bold ambition to expand globally, providing effective solutions in key therapeutic areas (including ophthalmology, dermatology, cardiometabolic, gastrointestinal, and general medicine).
Through its state-of-the-art facilities across the MEA region and dedication to regulatory excellence, Jamjoom Pharma continues to deliver products that meet the highest standards of safety, efficacy, and quality, improving health outcomes for millions of people.
Jamjoom Pharma Media Contact:
Vivian Fikry, Corporate Communications Director
M: +201222701256
E: Vivian.fikry@jamjoompharma.com
Send us your press releases to pressrelease.zawya@lseg.comDisclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.